Smolderen KG, Mena-Hurtado C, Zhao Z, Michalak W, et al. Lower risk of cardiovascular events in patients initiated on semaglutide 2.4 mg in the real-world: Results from the SCORE study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World). Diabetes Obes Metab 2025;27:6691-6704.
PMID: 40926360